other crops. Solazyme is making oils and specialty fats to sell at high margins to cosmetics and food companies, as is would-be microbial fuel-maker Amyris. The industry for “advanced biofuels is literally mm its infancy,” con- cedes Jonathan Wolfson, Solazyme CEO. The allure of Primus’s technology 1s i

ulting in him crashing and falling off one of the vehicles. Complaint attached I Read full article » INTELLECTUAL PROPERTY Cannabinoid Maker Hits Amyris With $881M Trade Secrets Suit A cannabinoid manufacturer slapped biotech company Amyris with an $881 million trade secrets suit Thursday, alleging

ad of Nestle Singapore 15 7 Expert in process and product development in industrial biotech and food tech. Advisory positions at Bolt Threads, Amyris, Miraculex AMYRIS. Jason Ryder, PhD n Bolt V Threads John SanGiovanni, PhD Chief of Unit on Genetics in Nutritional Neuroscience, National

her crops. Solazyme is making oils and specialty fats to sell at high margins to cosmetics and food companies, as is would-be microbial fuel-maker Amyris. The industry for "advanced biofuels is literally in its infancy," con- cedes Jonathan Wolfson, Solazyme CEO. The allure of Primus's technology is

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

e highlight two such agreements from the past few months below. Amyris / Undisclosed Partner (February 2019; Valued Up to $255MM) In February 2019, Amyris announced that it has signed an agreement for cannabinoid development, licensing, and commercialization in a partnership valued at up to $255MM (not